scholarly journals Hyperglycemia and Endothelial Dysfunction in Atherosclerosis: Lessons from Type 1 Diabetes

2012 ◽  
Vol 2012 ◽  
pp. 1-19 ◽  
Author(s):  
Steven Daniel Funk ◽  
Arif Yurdagul ◽  
A. Wayne Orr

A clear relationship between diabetes and cardiovascular disease has been established for decades. Despite this, the mechanisms by which diabetes contributes to plaque formation remain in question. Some of this confusion derives from studies in type 2 diabetics where multiple components of metabolic syndrome show proatherosclerotic effects independent of underlying diabetes. However, the hyperglycemia that defines the diabetic condition independently affects atherogenesis in cell culture systems, animal models, and human patients. Endothelial cell biology plays a central role in atherosclerotic plaque formation regulating vessel permeability, inflammation, and thrombosis. The current paper highlights the mechanisms by which hyperglycemia affects endothelial cell biology to promote plaque formation.

2021 ◽  
Vol 12 ◽  
Author(s):  
Gang Wang ◽  
Baihe Han ◽  
Ruoxi Zhang ◽  
Qi Liu ◽  
Xuedong Wang ◽  
...  

Hyperglycemia-induced endothelial cell senescence has been widely reported to be involved in the pathogenesis of type 2 diabetes mellitus‒accelerated atherosclerosis. Thus, understanding the underlying mechanisms and identifying potential therapeutic targets for endothelial cell senescence are valuable for attenuating atherosclerosis progression. C1q/tumor necrosis factor-related protein 9 (CTRP9), an emerging potential cardiokine, exerts a significant protective effect with respect to atherosclerosis, particularly in endothelial cells. However, the exact mechanism by which CTRP9 prevents endothelial cells from hyperglycemia-induced senescence remains unclear. This study aimed to investigate the effects of CTRP9 on hyperglycemia-induced endothelial cell senescence and atherosclerotic plaque formation in diabetic apolipoprotein E knockout (ApoE KO) mice. Human umbilical vein endothelial cells (HUVECs) were cultured in normal glucose (5.5 mM) and high glucose (40 mM) with or without recombinant human CTRP9 protein (3 μg/ml) for 48 h. Purified lentiviruses overexpressing CTRP9 (Lv-CTRP9) and control vectors containing green fluorescent protein (Lv-GFP) were injected via the tail vein into streptozotocin-induced diabetic ApoE KO mice. Results revealed that exposure of HUVECs to HG significantly increased the expression of Krüppel-like factor 4 (KLF4) and cyclin-dependent kinase inhibitor p21 (p21) and decreased that of telomerase reverse transcriptase (TERT). Treatment with recombinant human CTRP9 protein protected HUVECs from HG-induced premature senescence and dysfunction. CTRP9 promoted the phosphorylation of AMP-activated kinase (AMPK), attenuated the expression of KLF4 and p21 induced by HG, and increased the expression of TERT in HUVECs. Furthermore, in the background of AMPKα knockdown or KLF4 activation, the protective effects of CTRP9 were abolished. In-vivo experiments showed that the overexpression of CTRP9 inhibited vascular senescence and reduced atherosclerotic plaque formation in ApoE KO mice with diabetes. In conclusion, we demonstrate that KLF4 upregulation plays a crucial role in HG-induced endothelial senescence. This anti-atherosclerotic effect of CTRP9 may be partly attributed to the inhibition of HG-induced endothelial senescence through an AMPKα/KLF4-dependent mechanism, suggesting that CTRP9 could benefit further therapeutic approaches for type 2 diabetes mellitus‒accelerated atherosclerosis.


2006 ◽  
Vol 195 (6) ◽  
pp. S188
Author(s):  
Loralei Thornburg ◽  
Kristin Cushanick ◽  
Jeanne Peterson ◽  
Karin McCall ◽  
Robert Mooney ◽  
...  

2007 ◽  
Vol 20 (1) ◽  
pp. 103-109
Author(s):  
Paris J. Abrams

Diabetic peripheral neuropathy (DPN) is a complication of diabetes mellitus that occurs in both type 1 and type 2 diabetics. This complication is estimated to be prevalent in approximately 50% of the diabetic population and is associated with significant morbidity and mortality. Painful DPNs affect a minority of patients with DPN but are often chronic, severe, and debilitating. Many pharmacologic agents—including but not limited to pregabalin, duloxetine, tricyclic antidepressants, abapentin, and carbamazepine—have been studied and proven effective for the treatment of pain associated with DPN. Data from these studies were extracted and evaluated to compile a list of agents that are effective in treating painful diabetic neuropathies.


1983 ◽  
Vol 20 (4) ◽  
pp. 341-346
Author(s):  
Alberto Notarbartolo ◽  
Giovambattista Rini ◽  
Giuseppe Licata ◽  
Rosario Scaglione ◽  
Gaetana Fede ◽  
...  

2019 ◽  
Vol 57 (2) ◽  
pp. 125-132 ◽  
Author(s):  
Sara Machado ◽  
Rui Marques ◽  
Edite Nascimento ◽  
Ana Matos ◽  
Carla Henriques

Abstract Introduction. Diabetes Control and Complications Trial has established the importance of glycemic control in reducing the progression of retinopathy, nephropathy, and neuropathy in type 1 diabetics. There is little literature linking the frequency of glycemic monitoring with glycated hemoglobin A (HbA1c) in type 2 diabetics. The objectives were to assess the influence of glycemic self-monitoring on HbA1c in three groups of patients with type 2 diabetes (with insulin, with oral antidiabetics and with combination therapy). Methods. The glucometer capillary surveys of 117 patients were counted in the 30 days prior to the visit to the Integrated Diabetes Unit at Centro Hospitalar Tondela-Viseu. In the three groups considered, sociodemographic characteristics (age, gender, area of residence, household and schooling) were evaluated and compared. Results. There was no statistically significant association between HbA1c and the frequency of capillary glucose in any of the groups. In the evaluation of sociodemographic data, contrary to what was expected, the area of residence and schooling did not influence the value of HbA1c. Conclusion. These results question the role of glycemic monitoring in the metabolic control of type 2 diabetics, highlighting the need to implement therapeutic education programs so that these patients can adequately intervene in the therapeutic adjustment as a function of the information obtained by capillary glycemia.


2021 ◽  
Vol 12 ◽  
Author(s):  
Farzad Asadi ◽  
Savita Dhanvantari

Patients with diabetes mellitus exhibit hyperglucagonemia, or excess glucagon secretion, which may be the underlying cause of the hyperglycemia of diabetes. Defective alpha cell secretory responses to glucose and paracrine effectors in both Type 1 and Type 2 diabetes may drive the development of hyperglucagonemia. Therefore, uncovering the mechanisms that regulate glucagon secretion from the pancreatic alpha cell is critical for developing improved treatments for diabetes. In this review, we focus on aspects of alpha cell biology for possible mechanisms for alpha cell dysfunction in diabetes: proglucagon processing, intrinsic and paracrine control of glucagon secretion, secretory granule dynamics, and alterations in intracellular trafficking. We explore possible clues gleaned from these studies in how inhibition of glucagon secretion can be targeted as a treatment for diabetes mellitus.


Cornea ◽  
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Diana Patricia Amador-Muñoz ◽  
Valentina Conforti ◽  
Luisa Marina Matheus ◽  
Nicolas Molano-Gonzalez ◽  
César Payán-Gómez

PLoS ONE ◽  
2018 ◽  
Vol 13 (12) ◽  
pp. e0208905 ◽  
Author(s):  
Noel Pabalan ◽  
Raphael Enrique Tiongco ◽  
Jefferyl Kae Pandac ◽  
Noemi Anne Paragas ◽  
Shamar Lo Lasta ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document